NSCLC

This is the first-ever study in people to test a new cancer drug called TT125-802. The main goal is to find a safe dose and check for side effects in 50 adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will also look for early sig…

This study is testing a personalized treatment approach for people with locally advanced non-small cell lung cancer (NSCLC). It combines a new two-drug immunotherapy regimen (cemiplimab and fianlimab) with targeted radiation therapy. The goal is to see if this combination can bet…

This study is testing a drug called repotrectinib for people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug is safe and can shrink or control the brain tumors. It will enroll about 20 participants who wi…

This early-stage trial is testing a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The drug is designed to find and break down the faulty protein that drives this type of cancer. Researchers …

This early-stage study is testing a new drug called PRTH-101, both alone and combined with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors. The main goals are to find a safe dose, see how the body processes the drug, and check for ear…

This study is testing a new drug called STX-721/PFL-721 for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR or HER2 exon 20 insertions). The trial aims to find the safest and most effective dose while checking if the drug can shrink tumor…

This early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…

This early-stage study is testing a new drug called IDE161, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have spread. The main goals are to find safe doses and see if the treatment shows early signs of shrinkin…

This is a first-in-human study testing a new experimental drug called 212Pb-DOTAM-GRPR1 in adults with advanced cancers that have returned or spread. The main goal is to find a safe and tolerable dose. Researchers will also check if the drug, which delivers radiation directly to …

This study is testing an investigational drug called REGN5093 for people with advanced non-small cell lung cancer that has a specific genetic change called a MET alteration. The first part of the study aims to find a safe dose, and the second part will see how well that dose work…

This study is testing whether a new oral drug called daraxonrasib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change (RAS mutation) and has stopped responding to initial treatments. About 420 …

This is an early-stage study to test the safety and initial effectiveness of a new drug called RO7502175 for people with advanced solid tumors that have spread or cannot be cured. The drug will be tested both by itself and combined with other approved cancer drugs. The main goals…

This study is testing whether a new oral drug called TNG462 is safe and effective when combined with other cancer drugs for people with advanced pancreatic or non-small cell lung cancer. The trial will involve about 183 adults whose cancers have specific genetic changes (MTAP los…

This early-stage study is testing whether an experimental drug called NRM-823 is safe and can help control advanced cancers that have stopped responding to standard treatments. Researchers will give NRM-823 alone and combined with immunotherapy to about 150 adults with various so…

This is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…

This early-stage study is testing a new drug called VT3989, both alone and in combination with other cancer therapies. It aims to find a safe dose and see if it can help control advanced solid tumors and mesothelioma that have stopped responding to standard treatments. The trial …

This study is testing new combinations of experimental drugs for people with advanced solid tumors that have specific RAS mutations. Researchers want to see if combining a new type of drug called a RAS(ON) inhibitor with another cancer drug called ivonescimab is safe and can help…

This study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …

This study is testing a specific treatment sequence for people with advanced non-small cell lung cancer who cannot handle standard concurrent chemoradiation. It involves giving chemotherapy first, followed by a shorter, more intense course of radiation, combined with an immunothe…

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This early-stage trial is testing a new oral medication called NST-628 for adults with advanced solid tumors that have specific genetic changes in a key cancer growth pathway. The study aims to find a safe and effective dose and see if the drug can shrink tumors in patients who h…

This study is testing a new oral medication called Alintegimod, given alongside the immunotherapy drugs ipilimumab and nivolumab. It aims to see if this combination is safe and can help control advanced cancers that have spread or returned after other treatments. The study will e…

This study is testing whether combining an immunotherapy drug (toripalimab) with targeted radiation works better than combining it with standard chemotherapy when given before surgery for certain stages of non-small cell lung cancer. The goal is to shrink tumors more effectively …

This study is testing a personalized approach to treatment after surgery for early-stage lung cancer. It uses a sensitive blood test to check for tiny amounts of leftover cancer cells. Patients with no detectable cancer cells in two tests may be able to skip standard chemotherapy…

This early-stage study is testing a new drug called ONO-7428 in people with advanced solid tumors that cannot be surgically removed or have returned after treatment. The main goal is to find the highest dose that patients can tolerate safely and understand how the drug behaves in…

This early-stage study is testing the safety and early effectiveness of an experimental cancer treatment called T3011. The treatment is injected directly into tumors and is being tested both alone and combined with an existing immunotherapy drug (pembrolizumab) in people with adv…

This study is for people with a specific type of advanced lung cancer (ALK-positive NSCLC) that has spread to the brain but isn't causing major symptoms. It's comparing two treatment strategies: taking the targeted drug alectinib alone versus taking alectinib plus a precise form …

This is the first study in people to test a new drug called BBO-8520 for advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study will test BBO-8520 alone …

This study is testing whether using a lab test called OncoChoice to help select chemotherapy drugs can better control advanced non-small cell lung cancer that has spread and stopped responding to prior treatments. About 29 patients whose cancer has progressed after at least one p…

This study is testing if adding two treatments—a drug called narlumosbart and precise radiation therapy—to standard first-line chemo-immunotherapy can improve results for people with advanced non-small cell lung cancer that has spread to their bones. The goal is to see if this co…

This is a first-in-human study to check the safety and side effects of a new experimental drug called HLX37 in people with advanced or spreading solid tumors, including a type of lung cancer (NSCLC). The drug is designed to block two pathways that help tumors grow. The main goal …

This is a first-in-human study to test the safety and find the right dose of a new oral drug, OKN4395, for people with advanced solid tumors. The trial will give the drug alone and combined with an existing immunotherapy (pembrolizumab) to about 166 participants with cancers like…

This early-stage study is testing a new drug called RMC-5127 in adults with advanced cancers that have a specific genetic change called KRAS G12V. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other ca…

This study is testing if adding a precise, high-dose radiation treatment to liver tumors helps standard immunotherapy drugs work better for people with advanced lung cancer that has spread to the liver. It will compare the standard drug treatment alone to the drug treatment plus …

This study is testing a new type of radiation therapy called lattice radiation (LRT) for people with large cancer tumors that have spread to soft tissues. It compares LRT to standard radiation to see which is better at shrinking tumors and attracting immune cells to fight the can…

This study is testing a two-step treatment for advanced non-small cell lung cancer in patients whose previous targeted therapy has stopped working. First, patients receive a short course of chemotherapy, then switch to a different targeted drug called befotertinib. The goal is to…

This study is testing if combining immunotherapy drugs (called PD-1/PD-L1 inhibitors) with targeted radiation is more effective for controlling several advanced cancers, including lung and head/neck cancers. It aims to help patients live longer and also tries to find patterns in …

This study is testing a new drug called EP0031 for people with advanced cancers that have specific RET gene changes, including lung cancer. The goal is to find the right dose and see if the drug is safe and effective, especially for patients whose cancer has stopped responding to…

This study is testing whether a drug called BIO 300 can help protect the lungs of patients who have both early-stage lung cancer and a separate lung scarring disease (interstitial lung disease) when they receive radiation therapy. The main goal is to see if BIO 300 can prevent se…

This early-stage study is testing a new combination treatment for advanced non-small cell lung cancer (NSCLC) that has come back or stopped responding to standard therapies. It combines an experimental cell therapy called NK510 with existing PD-1 inhibitor drugs. The study will e…

This study is observing how well a combination of the immunotherapy drug sugemalimab and standard chemotherapy works for people with advanced non-small cell lung cancer (NSCLC) in real-world medical settings. It aims to see how long the treatment keeps the cancer from getting wor…

This study is testing a new drug called TUB-030 in adults with advanced solid cancers that have not responded to other treatments. The main goals are to find the safest dose and see if the drug helps control the cancer. It will focus on specific cancers like head and neck cancer …

This study is testing whether adding a second drug called OSE2101 to standard maintenance therapy can better clear tiny traces of cancer from the blood of advanced lung cancer patients. It involves 160 patients who have a specific genetic marker and have already completed initial…

This large, late-stage study is testing if adding a new drug called MK-2870 to a standard treatment helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will first receive a standard chemotherapy and immunotherapy combination. Then, t…

This study is for people with a specific type of lung cancer (non-small cell) who had surgery after initial treatment, but some cancer cells likely remain. It tests whether adding a personalized cell therapy (L-TIL), made from the patient's own immune cells, to a standard immunot…

This study is testing whether following a special fasting-mimicking diet while receiving standard immunotherapy can help fight advanced non-small cell lung cancer. Researchers want to see if this diet makes the cancer more vulnerable to treatment and reduces side effects. The stu…

This study is testing whether adding two new immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy works better for people with stage III non-small cell lung cancer that cannot be removed by surgery. The trial will enroll 33 patients who haven't had previous…

This study is testing whether adding a special surgical sealant during lung cancer surgery helps patients recover faster. Researchers will compare patients who get the sealant with those who get standard surgery to see if it reduces air leaks, a common complication. The main goal…

This study is testing an experimental drug called YL202 in people with advanced solid tumors that have spread or can't be removed by surgery. The trial aims to see if YL202 can shrink tumors and control cancer growth while monitoring side effects. It will enroll 200 adults in Chi…

This is the first study testing the experimental drug TORL-1-23 in people. Researchers aim to find a safe and effective dose for patients with advanced solid tumors, including ovarian, endometrial, and lung cancers. The study will enroll 90 participants to monitor side effects an…

This study compares two radiation methods for patients whose cancer has spread to the brain and who are receiving immunotherapy. Researchers want to see if giving smaller radiation doses over several days causes fewer side effects than the standard single-day treatment. The trial…

This study is testing an experimental drug called HC010 for people with advanced non-small cell lung cancer who have not yet received treatment for their advanced disease. The trial will enroll 50 adults with specific cancer characteristics (PD-L1 positive) to see how well HC010 …

This study is comparing two different radiation treatments for patients with 4-15 brain metastases (tumors that have spread to the brain from cancer elsewhere in the body). It aims to see if a more targeted, shorter treatment (CyberKnife radiosurgery) is as effective as the stand…

This is the first human study of an experimental drug called SLV-154 for people with advanced solid tumors that have spread. The main goal is to find the highest safe dose and understand how the body processes the drug. About 70 adults with one of ten specific advanced cancers wh…

This study is testing whether combining a targeted drug (adagrasib) with precise radiation to the brain (stereotactic radiosurgery) can better control lung cancer that has spread to the brain. It is for up to 30 adults with a specific type of advanced lung cancer (KRAS G12C-mutat…

This study is testing whether a lower dose of chemotherapy, when combined with immunotherapy, is safer and easier to tolerate for older or frail adults with advanced lung cancer. The main goal is to see if this gentler approach causes fewer severe side effects that would force pa…

This study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have come back or spread. The therapy, called Tmod CAR T, is designed to recognize and kill cancer cells while using a built-in safety switch to protect the patient's healthy …

This study is testing whether adding an experimental drug called EIK1001 to standard chemotherapy and immunotherapy helps people with advanced lung cancer. It will involve about 70 adults with stage 4 non-small cell lung cancer who haven't had treatment for their advanced disease…

This study is testing a new blood test to see if it can predict whether immunotherapy will work for patients with advanced lung cancer. Researchers will track 170 patients receiving standard immunotherapy to see if changes in tumor DNA in their blood can signal treatment failure …

This study aims to understand how lung cancer patients' immune systems respond to immunotherapy drugs. Researchers will track whether patients develop antibodies against their immunotherapy medications and whether these antibodies affect treatment effectiveness or side effects. T…

This study aims to develop a tool that can predict how well patients with non-small cell lung cancer will respond to treatment before surgery. Researchers will collect various types of data from 500 patients receiving chemo-immunotherapy followed by surgery. The goal is to create…

This study aims to understand how lung cancer changes as it spreads to other parts of the body. Researchers will analyze tumor samples from 25 patients with non-small cell lung cancer to compare the original tumor with where it has spread. The goal is to identify molecular differ…

This study is testing whether a special type of PET/CT scan can predict how well a new targeted drug works for advanced lung cancer. Researchers will give the scan to 50 patients before and during their treatment to see if early scan results match their long-term response. The go…

This study aims to collect tumor tissue and blood cells from people with advanced solid tumors to prepare for future CAR T-cell therapy. Researchers will analyze the cancer tissue to understand how tumors hide from the immune system and collect participants' own immune cells thro…